Evidence Level V — Preclinical Only (No Published Human Clinical Trial)
BPC-157 has an extensive rodent and in vitro research record spanning tendon, gut, bone, cardiovascular, and neurological repair models. As of 2025, no peer-reviewed human Phase I or Phase II clinical trial has been published. Virtually all published studies originate from a single Croatian research group (Sikiric and colleagues). Independent replication in separate research groups is limited. The evidence base is mechanistically compelling but scientifically unvalidated in humans. This profile presents the preclinical record with full disclosure of these limitations.
Discovery & Molecular Structure
Gastric Origin · Synthetic Analog · Acid-Stable Pentadecapeptide
Origin & Discovery
Sikiric et al. — Gastric Protective Protein Isolation
BPC-157 was isolated and characterized by Professor Predrag Sikiric and the Zagreb research group from a larger gastric juice protein (~4,200 aa) known as BPC (Body Protection Compound). The original BPC protein demonstrates cytoprotective activity in the gastrointestinal mucosa. The 15 amino acid segment (positions 157–171 of the native protein) was synthesized and shown to retain and amplify the repair-promoting biological activity. The synthetic pentadecapeptide designation BPC-157 refers to this isolated fragment. Isolation methodology: Sikiric P et al. Life Sciences 1993.
Derived from human gastric juice protein — not animal-derived
Gastric Stability Advantage
Acid-Resistant Pentadecapeptide Architecture
Most peptides are hydrolyzed rapidly in the stomach (pH 1.5–3.5) and intestinal pepsinase/trypsin environment, rendering oral administration ineffective. BPC-157's sequence resists gastric acid proteolysis — consistent with its origin as a fragment of a protein found in and produced by the gastric mucosa itself, which must survive the gastric environment. This acid stability underlies the use of oral BPC-157 formulations (particularly as the BPC-157 Arginate salt, a more soluble form). Oral bioavailability is estimated at approximately 15–30% in rodent models; no human pharmacokinetic data exist.
3 consecutive Pro residues (positions 3–5) — Pro-rich regions confer proteolytic resistance
Mechanism of Action
NO / VEGF / FAK-Paxillin / NF-κB / GH-GHSR Cross-Talk
BPC-157 does not act through a single, well-characterized receptor. Instead, it appears to modulate several tissue repair pathways simultaneously — which may explain its multi-system activity across different organ models but also makes receptor-level mechanistic clarity challenging. The NO pathway and VEGF angiogenic axis are the best-documented primary mechanisms.
Primary — NO/eNOS Axis
Nitric Oxide Pathway Upregulation
BPC-157 upregulates endothelial NO synthase (eNOS) expression and activity → increased NO production → cGMP-mediated vasodilation and improved tissue perfusion. NO also promotes wound healing, inhibits platelet aggregation, and supports fibroblast activity. BPC-157's NO-upregulating effect has been demonstrated in tendon, gut, and cardiovascular rodent models.
↑ eNOS expression in injured tissue (rodent)
Primary — Angiogenesis
VEGF-Mediated Neovascularization
BPC-157 stimulates VEGF (vascular endothelial growth factor) production in fibroblasts and endothelial progenitor cells. In tendon repair models, new vessel formation into avascular connective tissue is a rate-limiting step in healing — BPC-157's VEGF upregulation accelerates this neo-vascularization. VEGF induction correlated with increased collagen cross-linking in Achilles tendon transection studies.
↑ VEGF in tendon repair tissue (rodent)
FAK/Paxillin Pathway
Fibroblast Migration & Collagen Synthesis
BPC-157 activates focal adhesion kinase (FAK) and its adaptor paxillin — key regulators of fibroblast cell spreading, migration into wound matrices, and collagen synthesis signaling. FAK activation promotes fibroblast-to-myofibroblast transition critical for wound contraction and repair architecture. Tendon fibroblast cell culture studies show dose-dependent in vitro proliferation and migration responses.
↑ FAK/paxillin in fibroblast culture models
Anti-Inflammatory
NF-κB Pathway Suppression
BPC-157 inhibits NF-κB nuclear translocation → reduced transcription of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6). This anti-inflammatory effect is proposed as a mechanism for its gut protective effects in NSAID-induced ulcer, IBD, and anastomosis models. Anti-inflammatory activity may also protect peritendinous tissue in musculoskeletal repair contexts.
↓ NF-κB, IL-1β, TNF-α in GI models (rodent)
CNS/GH Axis — Exploratory
GH/GHSR-1a Receptor Interaction
A subset of BPC-157 studies (Sikiric group) suggests interaction with GH receptor and GHSR-1a (ghrelin receptor) signaling in brain and gut. Proposed role in dopaminergic modulation (protecting against 6-OHDA dopamine depletion in Parkinson's models). This pathway is the most speculative; the receptor binding characterization is incomplete and has not been independently verified.
Exploratory — no confirmed receptor characterization
Gut / GI Protection
Mucosal Cytoprotection
In the GI tract — the biological context of BPC-157's origin — it promotes epithelial cell survival, reduces NSAID-induced permeability, accelerates gastric ulcer healing, and supports post-anastomosis colonic repair. Combined NO, NF-κB, and VEGF activity converges on the mucosal healing axis. This is the most internally consistent mechanistic cluster and the area with the deepest (though still preclinical) evidence base.
Gastric ulcer healing ↑ in multiple rodent models
Receptor Identification Gap: Unlike peptides with characterized receptor binding (PT-141: MC3R/MC4R; Tesamorelin: GHRHR; AOD-9604: β3-AR), BPC-157's primary receptor has not been definitively identified. Its biological effects appear to operate via pathway-level modulation rather than a discrete receptor-agonist interaction. This limits mechanistic predictions of drug–drug interactions, tissue specificity, and dose-response modeling. Independent receptor characterization research is a critical gap in the BPC-157 literature.
Multi-System Tissue Target Map
All Evidence Level V · Rodent Models
BPC-157 is unique among research peptides in demonstrating repair activity across six distinct tissue systems in preclinical models. Whether this breadth reflects a fundamental tissue-repair signaling mechanism or is an artifact of model-specific conditions is a key open question in the field.
🦾
Tendon & Ligament
Level V
Achilles tendon transection model: 2–3× faster healing by tensile strength recovery at 2–4 weeks. Medial collateral ligament transection: accelerated fibroblast repopulation and collagen cross-linking. Most-replicated tissue target in BPC-157 literature.
🫁
Gastrointestinal Mucosa
Level V
NSAID-induced gastric ulcer healing, stress ulcer prevention (water immersion restraint stress model), Crohn's/IBD analogs, and colonic anastomosis leak reduction. Deepest and most internally consistent tissue evidence base.
🦴
Bone & Periosteum
Level V
Fracture healing acceleration in femur fracture rodent models: increased callus formation, earlier cortical bridging. Periodontal tissue studies (Zagreb group) show alveolar bone preservation in extraction socket models — potentially relevant to dental repair contexts.
💪
Skeletal Muscle
Level V
Crush injury and laceration models: accelerated myofiber repair and reduced fibrosis at injury site. Corticosteroid-induced myopathy model: BPC-157 co-administration attenuated dexamethasone-mediated muscle weakness and fiber atrophy — relevant for patients on chronic steroids.
❤️
Cardiovascular
Level V
Arrhythmia models (aconitine, ouabain-induced): BPC-157 reduced arrhythmia severity. Pulmonary hypertension model: reduced pulmonary artery remodeling. Coronary ligation model: reduced infarct size with immediate post-ligation BPC-157 (NO-dependent). All mechanistic, no human translation.
🧠
CNS / Neuroprotection
Level V
6-OHDA dopamine depletion model: BPC-157 reduced bradykinesia-like symptoms and dopamine loss. Traumatic brain injury (weight drop model): reduced neuronal apoptosis and improved behavioral performance. Spinal cord injury: reduced lesion size (intralesional BPC-157). Speculative but broadly referenced in the literature.
Preclinical Evidence Review
All Level V · Animal Models · Predominantly Sikiric Research Group
Critical Editorial Disclosure: No peer-reviewed human Phase I, Phase II, or Phase III clinical trial for BPC-157 has been published as of 2025. The studies below are preclinical animal models only. The evidence base — while mechanistically compelling — does not meet the standard required for evidence-based clinical prescribing. The dominant limitation of the BPC-157 literature is its near-total dependence on a single research group; the replication gap is addressed explicitly in the section following these study cards.
Krivic A, Sikiric P et al. · J Orthop Res. 2006 · Zagreb Group
Model: Complete Achilles tendon transection in Wistar rats. BPC-157 10 mcg/kg SC daily vs. saline control.
Primary outcome: Tensile strength by load-to-failure testing at 2 and 4 weeks post-transection.
Results: BPC-157 group achieved ~68% of native tendon load-to-failure at 4 weeks vs. ~24% in controls — approximately 2.8× greater recovery of tensile strength by week 4.
Histology: Earlier collagen fiber alignment, increased fibroblast density at wound margin, and neovascular ingrowth at 2 weeks in BPC-157 group.
Limitation: Single species, single dose, same research group as originating discoveries — not independently replicated in this exact model by a separate group.
Level V · Rodent
NSAID-Induced Gastric Ulcer — Cytoprotection
Sikiric P et al. · J Physiol Paris. 2000 · Zagreb Group
Model: Indomethacin 30 mg/kg PO in Wistar rats — an aggressive NSAID ulceration model with near-universal mucosal lesion formation.
BPC-157 given 10 mcg/kg intraperitoneally either simultaneously with indomethacin (preventive) or 1 hour post-indomethacin (therapeutic).
Results: Both preventive and therapeutic administration significantly reduced ulcer index score. At 24h, BPC-157 reduced mean mucosal lesion area by ~80% vs. vehicle. Prevention arm showed near-complete ulcer suppression.
Mechanism confirmed: eNOS knockdown mice showed attenuated BPC-157 cytoprotection — supporting the NO-dependence of the effect.
Clinical implication (preclinical inference): IBD, post-NSAID gastropathy, and anastomosis patients as potential research candidates — no human trial has evaluated this.
Novinscak T, Sikiric P et al. · J Orthop Res. 2008 · Zagreb Group
Model: Rats treated with dexamethasone 1 mg/kg/day × 7 days — established model of corticosteroid-induced proximal myopathy.
BPC-157 10 mcg/kg SC co-administered daily during dexamethasone course.
Results: BPC-157 co-treatment significantly attenuated dexamethasone-induced reduction in grip strength (−20% vs. −52% in steroid-only group). Histology: reduced Type II fiber atrophy; decreased myosin heavy chain degradation markers.
Mechanism: proposed via FAK/paxillin fibroblast-myocyte pathway and NO-mediated anti-catabolic signaling; not mechanistically confirmed in this study.
Potential application inference: patients on chronic corticosteroids for inflammatory conditions. No human data exist.
Level V · Rodent
6-OHDA Parkinson's Model — Dopaminergic Protection
Sikiric P et al. · J Physiol Pharmacol. 2016 · Zagreb Group
Model: 6-hydroxydopamine (6-OHDA) stereotaxic injection into medial forebrain bundle — standard rodent Parkinson's model causing dopaminergic nigrostriatal depletion.
Results: BPC-157 group showed significantly less rotational behavior on apomorphine challenge (surrogate for D2 receptor supersensitivity/dopamine depletion severity). Striatal dopamine concentration measured at 4 weeks was ~45% higher in BPC-157 group vs. vehicle (p<0.05).
Mechanism proposed: GH/GHSR-1a pathway interaction preserving dopaminergic neuron survival; NO-mediated neuroprotection; direct anti-oxidant effect on 6-OHDA radical cascade. No single mechanism confirmed.
Context: Parkinson's disease model research is speculative at BPC-157's current evidence level. Explicitly exploratory.
This study is notable as one of the few BPC-157 publications NOT from the Sikiric/Zagreb group — providing partial independent in vitro replication.
Primary tendon fibroblasts isolated from human tendons, cultured with BPC-157 at concentrations 0.1–100 μg/mL for 48–96h.
Results: BPC-157 at 1–10 μg/mL significantly increased fibroblast proliferation (MTT assay, ~1.7× at 10 μg/mL) and migration (scratch wound assay, ~2.2× closure rate vs. control at 24h).
Western blot: increased FAK and paxillin phosphorylation — mechanistically supporting the FAK/paxillin hypothesis in human-derived cells, not only rodent tissue.
Limitation: In vitro results do not confirm in vivo or clinical efficacy; concentration used (μg/mL range) is substantially higher than physiologic concentrations achievable with SC dosing.
Independent Replication Gap — The Central Limitation of BPC-157 Evidence
Near-total Sikiric group dominance: Searching PubMed for "BPC-157" returns >200 papers; an estimated >185 are from Professor Predrag Sikiric's Zagreb group or direct collaborators. Science depends on independent replication — a single-group research program, however internally consistent, cannot substitute for multi-center corroboration.
No published human trial: No Phase I (safety/PK), Phase II (dose-ranging/preliminary efficacy), or Phase III (efficacy) trial for BPC-157 in any indication has been published in a peer-reviewed journal as of 2025. This is the single most important factual limitation for any clinician evaluating this compound.
Partial independent replication: The Chang et al. 2011 Taiwan study (tendon fibroblasts), Tkalcevic et al. (2007, TNF-α IBD model, partial independence), and limited Croatian orthopedic group studies provide some non-Zagreb corroboration at the in vitro and rodent level — but this is far from adequate independent clinical validation.
Why no human trial? The compound is not patentable in its basic form (natural gastric peptide sequence) — making it commercially unattractive for the Phase III investment required for FDA approval. This is a structural market failure, not necessarily scientific failure. Compounding pharmacies make BPC-157 available off-protocol, bypassing the trial pathway entirely.
What replication exists suggests reproducibility: The in vitro Chang et al. 2011 FAK/paxillin data independently confirm the fibroblast mechanism. The NO-dependence has been replicated (eNOS-KO attenuation). The gastric stability property is independently confirmed by gastric acid stability testing. The negative aspects of the replication gap are real, but not complete nullification of all evidence.
Editorial position: BPC-157 is a mechanistically plausible, preclinically intriguing compound whose human evidence base is currently zero. It should be discussed with research candidates as an exploratory compound with no established human dose-response, no human safety profile, and no human efficacy data. This does not preclude research-candidate counseling; it defines the boundaries of what can ethically be communicated.
Subcutaneous vs. Oral Route
Administration Route Selection · Acid Stability Advantage · No Human PK Data
BPC-157 is unique among research peptides in having a plausible oral route due to its acid-stable pentadecapeptide structure. The oral vs. SC route decision is an active area of research community discussion without direct head-to-head human pharmacokinetic data.
Subcutaneous Injection — Standard Research Route
Bypasses GI first-pass degradation entirely — highest systemic exposure
Best-validated route in animal studies: most published data use SC or IP injection
Predictable dosing — no oral bioavailability variability from food or GI transit
Estimated bioavailability: ~90%+ systemic exposure (as with other SC peptides)
Requires injection; patient compliance and technique considerations
No human PK data (t½, Cmax, Tmax) available; rodent data suggest relatively short half-life (~30–60 min)
Oral Administration — BPC-157 Arginate Salt
BPC-157's acid stability relative to other peptides allows partial oral bioavailability (~15–30% in rodent models)
Arginate salt form increases solubility and may further improve GI absorption relative to standard lyophilized BPC-157
Potential preference for GI-targeted applications (IBD, NSAID gastropathy, anastomosis) where local mucosal concentrations may exceed systemic SC dosing
Lower systemic exposure than SC — not preferred for musculoskeletal, cardiovascular, or CNS targets requiring systemic circulation
No human bioavailability data. Rodent oral bioavailability cannot be assumed to translate (human GI transit time, pepsin activity, and mucosal absorptive surface differ).
BPC-157 Arginate is a relatively newer compounding preparation; independent purity/stability verification data are limited
Human Dosing: Why None Is Published Here
Animal → HED Extrapolation Only · No Clinical Trial Dose Exists · Not Self-Administration Guidance
No Established Human Dose: BPC-157 has no FDA-approved indication, no published Phase I dose-escalation trial, and no established human pharmacokinetic profile. Because no controlled human dosing study has ever been conducted, PeptideReport.ai does not publish a dosing amount, injection schedule, or cycle length for BPC-157 — for this compound or any other. The figures below illustrate how a rodent research dose is translated into a scientific human-equivalent-dose (HED) estimate; they describe a calculation, not a recommendation.
Animal Research Dose (Rat)
10 mcg/kg
SC or IP daily in most efficacy studies; some studies use 1–100 mcg/kg range
HED Extrapolation (÷6.2 rat→human)
~1.6 mcg/kg
~110–115 mcg for a 70 kg adult, by the FDA allometric scaling formula — a reference calculation, not a dose
Estimated Half-Life (Rodent SC)
~30–60 min
Rodent data only; no human pharmacokinetic study has measured this in people
On the Ranges Circulating Online: Dosing ranges commonly cited in online research communities (spanning roughly 200 mcg to 2 mg/day, across subcutaneous and oral routes) did not come from a controlled human trial and run several-fold above the allometric HED shown here. PeptideReport.ai does not reproduce those figures as guidance, and no dose, frequency, route, or cycle length should be inferred from anything on this page. Anyone considering BPC-157 should raise it directly with a physician who can evaluate it against their own health history — self-administration decisions made from information found online are exactly the scenario this evidence gap makes risky.
Sourcing & Regulatory Considerations
Compounding Pharmacy vs. Research-Chemical Vendors · Regulatory Status
BPC-157 is not an FDA-approved drug. PeptideReport.ai does not provide reconstitution, storage, or self-injection instructions for it or any other research peptide — that guidance belongs with a prescribing or compounding physician and pharmacist, not a public web page. The considerations below are regulatory and sourcing context, not a preparation or purchasing guide.
Source Quality Warning: Research-chemical suppliers (non-pharmacy vendors) are not held to the sterility, endotoxin, or purity standards required of licensed compounding pharmacies (503A/503B facilities), and purity claims on research-chemical websites are not independently verifiable. PeptideReport.ai does not name, link to, or recommend any specific vendor, pharmacy, or supplier. Sourcing questions belong in a conversation with a physician or licensed compounding pharmacist, not with an online retailer.
Regulatory Status: BPC-157 is not FDA-approved for any indication, and peptide compounding eligibility has been an active and evolving area of FDA review — research candidates and physicians should confirm current status with a licensed pharmacist rather than assume continued availability. Any preparation, reconstitution, or administration of a compounded peptide should be carried out by a licensed pharmacy and supervising physician, never by an individual following instructions found online, including on this page.
Safety Profile
Preclinical Safety Data · No Human Long-Term Data · Compounding Quality Variable
💉
Acute Rodent Toxicology
No Acute Toxicity Observed
LD50 not reached in rodent acute toxicity studies up to very high doses (mg/kg range). No organ toxicity on standard histopathology at research doses in subacute rodent studies (Sikiric group data).
🔬
VEGF / Angiogenic Risk
Theoretical Concern — No Human Data
VEGF upregulation is a known tumor angiogenesis promoter. In cancer biology, VEGF drives tumor neovascularization. Whether BPC-157's VEGF induction at research doses promotes neoplastic vascularization in humans is completely unknown. Patients with active or recent malignancy should not use BPC-157 under any research context without oncology consultation.
🏥
Human Safety Reports
Informal Only — No Published Data
Adverse effects in human users are primarily reported via online research communities, not peer-reviewed case reports. Commonly mentioned: mild injection site reactions, headache, GI upset (oral form), and dizziness. No serious adverse events have been formally documented in published case series.
🫀
Cardiovascular Effects
NO-Mediated Vasodilation (Likely Benign)
eNOS upregulation and NO-mediated vasodilation could theoretically lower blood pressure. Rodent cardiovascular studies show protective, not damaging, effects at research doses. Patients on antihypertensives or nitrates should monitor blood pressure; additive vasodilatory effects are theoretical.
💊
Compounding Quality
Variable — Unregulated
BPC-157 is produced by multiple compounding pharmacies and research chemical suppliers with variable GMP compliance. Purity, endotoxin levels, and lyophilization stability vary by source. Third-party certificate of analysis review is recommended before any human use.
🤰
Pregnancy / Reproduction
No Data
No reproductive toxicology, teratogenicity, or developmental studies in humans or primates. BPC-157 should not be used in pregnancy, lactation, or in women planning pregnancy. VEGF pathway modulation during organogenesis is a theoretical developmental risk.
Research Candidate Framework
Preclinical Evidence Only · Exploratory Research Context
Framework Scope: The following is not a prescribing guide. It describes which research candidate profiles have the strongest preclinical mechanistic rationale for BPC-157 discussion — given the absence of any human RCT, "ideal candidate" designations are mechanistic inferences only.
✓Stronger Mechanistic Rationale
Tendon or ligament injury (partial tear, chronic tendinopathy): deepest preclinical evidence base; highest internal consistency across rodent models; most commonly cited indication by clinician early adopters
Post-surgical recovery (tendon-to-bone repair, anastomosis): animal model evidence for accelerating structural repair — strongest rationale for procedural contexts with defined repair timelines
Inflammatory bowel disease or NSAID-induced gastropathy: gastric origin of BPC-157 provides mechanistic face validity; oral route concentrates compound at GI target; multiple ulcer models show effect
Chronic corticosteroid users: corticosteroid myopathy model shows muscle-protective effect; mechanistically plausible for patients on long-term dexamethasone, prednisone, or similar
Active fitness/athletic population: motivated self-experimenter with high health literacy who understands Level V evidence limitations and accepts research candidacy with full informed-uncertainty disclosure
✗Contraindicated / Poor Rationale
Active or recent malignancy: VEGF upregulation is a tumor angiogenesis mechanism; potential to promote neoplastic vascularization is a non-negotiable concern with current evidence limitations
Patients seeking FDA-validated treatment with established efficacy: BPC-157 is not that compound; patients requiring evidence-based therapy should be directed to appropriate standard-of-care
Pregnancy, lactation, or planning conception: no reproductive safety data; VEGF modulation during organogenesis is a theoretical developmental concern
Patients who will interpret preclinical animal data as equivalent to human clinical evidence: candidate education must be complete; if the patient cannot distinguish Level V from Level I, they are not ready for research candidacy counseling
Primary goal: body recomposition or fat loss — BPC-157 has no established metabolic or adipose mechanism; AOD-9604 or MOTS-c are mechanistically more appropriate for that intent
Comparator Landscape
Tissue Repair Peptides · By Evidence Level and Mechanism
Equine veterinary data provides broader multi-species replication than BPC-157; similar human evidence gap; full Thymosin β4 is a scheduled substance in sport (WADA)
Topical application route allows localized dermal/wound delivery without systemic exposure; better manufacturing availability; narrower tissue range than BPC-157
PRP (Platelet-Rich Plasma)
Autologous growth factor concentrate (PDGF, TGF-β1, VEGF, FGF) released at injection site
Level Ib
Intra-articular / Intratendinous
Tendon (lateral epicondyle, Achilles), OA, wound
Level Ib evidence (systematic reviews, multiple RCTs for some indications); autologous eliminates immune rejection; no exogenous compound; higher evidence base than any research peptide for tendon indications
Level IIb human data vs. BPC-157's Level V; IGF-1 elevation drives collagen production but requires cancer/DM monitoring; more established PK profile
PRP vs. BPC-157 for Tendon Injuries — Evidence-Based Hierarchy: For patients with tendinopathy or partial tendon tears seeking evidence-based care, PRP has Level Ib evidence (systematic reviews, multiple RCTs) for several tendon indications. BPC-157 has Level V preclinical-only evidence. This comparison does not dismiss BPC-157's research potential — it establishes the evidence hierarchy for shared decision-making. Research candidates should understand that the current evidence base for BPC-157 tendon repair in humans does not exist, while PRP evidence does.
For a full side-by-side analysis of these two tissue-repair peptides — mechanisms, preclinical records, and where each evidence base falls short — see the dedicated comparison page.
BPC-157 + TB-500: The Tissue Repair Stack
Mechanistic Rationale for Combination · Complementary Pathways · Level V for Both Agents
BPC-157 and TB-500 (Thymosin β4 / Tβ4) are the most frequently co-administered research peptides in musculoskeletal recovery contexts. Unlike combinations chosen by anecdote, this pairing has a mechanistically coherent rationale: the two peptides act on distinct phases and cellular targets in the tissue repair cascade. This section examines the evidence behind the stack — and the important caveat that both agents are Level V individually, and there are zero published combination studies in any organism.
Down-regulates inflammatory gene expression via MRTF-A sequestration; mild anti-inflammatory role
Proliferative Days 3–21
Peak activity: VEGF neovascularization of avascular zones + FAK/paxillin fibroblast proliferation → collagen deposition begins
Peak activity: actin remodeling for fibroblast migration into clot scaffold; CD34+ progenitor homing amplifies cell availability at repair site
Remodeling Weeks 3–12+
Continued VEGF maintenance of neo-vascular network; ongoing NF-κB suppression prevents chronic inflammatory cycling
SRF target gene regulation for collagen I vs. III ratio maturation; cytoskeletal organization for tensile strength recovery
No Stack Protocol Published: PeptideReport.ai does not publish a dosing, injection, or cycle-length protocol for the BPC-157 + TB-500 combination. Beyond the individual evidence gaps documented above, there are zero published studies — in any organism — evaluating the two peptides together, so no combination dose, ratio, or schedule has ever been tested for safety or interaction effects. Evidence level: V for both agents individually; no data exists at any evidence level for the combination. Interest in this pairing should be raised with a physician, not assembled from protocols found online.
Independent Evidence Gap for TB-500: Like BPC-157, TB-500 (Thymosin β4) also suffers from significant single-group research dominance — with much of the original basic science from a small number of investigator groups. Unlike BPC-157, TB-500 has reached early Phase I/II exploration for specific indications (cardiac ischemia, dry eye disease — RegeneRx Biopharmaceuticals trials, ~2010–2018), providing at least some human pharmacokinetic and safety precedent. Those trials used different delivery routes and doses than the SC injection protocol above. Neither agent has a published human RCT for musculoskeletal indications.
Path to Human Evidence
What It Would Take to Move BPC-157 from Level V to Level I
The Replication Gap section documents the current state of BPC-157 evidence. This section addresses the forward-looking question: what clinical research program would be required to move BPC-157 from Level V (preclinical only) to a level that meets evidence-based medicine standards? Understanding this pathway helps physicians frame the gap clearly when counseling research candidates.
I
Level I — Systematic Review / Multiple RCTs
Multiple independent, well-powered Phase III RCTs with consistent findings, synthesized in systematic review and meta-analysis. FDA approval for a specific indication would place a compound here. Distance from current state: requires completion of Levels IIb → Ib first. Estimated timeline if a Phase I was initiated in 2025: 10–15+ years minimum.
Ib
Level Ib — Single Well-Powered Phase III RCT
A single, properly powered, multicenter, double-blind, placebo-controlled Phase III trial with pre-registered primary endpoints and independent statistical analysis. Requires prior IND approval, Phase I safety data, and Phase II dose-finding data. Estimated cost: $20M–$100M+ depending on indication and endpoint complexity.
IIb
Level IIb — Phase II Proof-of-Concept RCT
A randomized, placebo-controlled Phase II trial with biomarker or clinical outcome endpoints. n=60–200 per arm. Primary purpose: dose optimization, endpoint selection, and signal detection before powering a Phase III. Representative design for tendinopathy: 12-week DBPC RCT with MRI T2 mapping + VISA score as co-primary endpoints. For IBD: endoscopic mucosal healing at 8 weeks + CDAI. Requires IND and Phase I safety completion.
III
Level III — Controlled Non-Randomized / Observational Cohort
Prospective registries, case series with controls, or retrospective comparative cohort studies. Intermediate evidence that can justify Phase II trial design but does not substitute for a randomized controlled trial. Currently absent for BPC-157 — no prospective registry of clinician-administered cases with systematic outcome documentation exists in the published literature as of 2025.
IVa
Level IVa — Phase I Human Safety & Pharmacokinetics
Open-label dose escalation in healthy volunteers. Primary objectives: establish safe dose range, characterize human pharmacokinetics (AUC, Cmax, t½, bioavailability by route), and document adverse event profile. n=24–48 subjects typical. Requires IND filing with FDA; IND application would submit all existing preclinical safety data. This is the immediate next step needed and does not yet exist. Estimated cost: $2M–$8M.
V
▶ BPC-157 Current Position
Level V — Preclinical Animal Models Only
The entirety of BPC-157's published efficacy literature is rodent model data, predominantly from a single investigator group. No Phase I trial has been published. No IND appears to have been filed with the FDA for efficacy evaluation. The compound exists in a gap between compelling preclinical biology and the first human safety study.
Most Feasible Phase I Target Design
Proposed Phase I/IIa Trial Concept — Patellar Tendinopathy Model
IndicationChronic patellar tendinopathy (Jumper's Knee) — chosen for: objective imaging endpoint (MRI T2 mapping / ultrasound elastography), validated patient-reported outcome (VISA-P scale 0–100), high unmet need in athletic population, and no adequate pharmaceutical standard of care beyond eccentric loading protocol
DesignPhase I/IIa adaptive design: dose escalation (Phase I, n=24, 3 cohorts × 8 subjects) followed by randomized placebo-controlled Phase IIa signal detection (n=60 per arm, 2:1 BPC-157:placebo)
Dose GroupsCohort A: 100 mcg SC/day · Cohort B: 250 mcg SC/day · Cohort C: 500 mcg SC/day — chosen to bracket clinician-reported range and the allometric HED (~115 mcg) with the empirically used higher range
Primary EndpointsPhase I: Safety (AE/SAE rate), PK parameters (AUC, Cmax, t½, bioavailability). Phase IIa: VISA-P score change at 12 weeks; MRI T2 mapping tendon signal intensity change at 8 weeks
Key EligibilityAge 18–50; chronic patellar tendinopathy ≥3 months; failed 6-week eccentric loading protocol; VISA-P <70 at baseline; no active malignancy; no prior peptide exposure within 12 months; eGFR >60; no pregnancy; MRI-confirmed tendinopathic signal on T2
Estimated SamplePhase I: 24 (safety/PK). Phase IIa: 180 (60/arm, 2:1 ratio). Total: ~204 subjects across 3 sites over 30 months
Estimated Budget$4M–$9M (Phase I component ~$2M; Phase IIa component ~$4–7M depending on imaging endpoints and site costs). Academic medical center investigator-initiated trial model reduces cost vs. industry-sponsored
Why No Trial Has Been Initiated — Obstacles Analysis
💰
Commercial Incentive Problem
BPC-157 is a short, well-characterized peptide with no remaining patent protection in its natural sequence. Pharma companies have limited ability to recoup the $100M+ cost of Phase III trials from a compound any competitor can compound and sell. The commercial model (compounding pharmacy distribution) is not structured to fund clinical trials. Orphan drug designation or NIH investigator grants are the most realistic funding pathways.
📋
FDA Regulatory Status Gap
BPC-157 occupies an ambiguous regulatory position: it is a drug under the Federal Food, Drug, and Cosmetic Act but is not FDA-approved and no IND appears to be on file for efficacy evaluation. Filing an IND requires the sponsor to compile all existing preclinical data — a feasible step, but no research group or commercial entity has taken it for the primary indications (tendinopathy, GI). FDA's 2022 actions against certain compounding peptides created further regulatory uncertainty.
🔬
Single-Group Replication Problem
Regulatory agencies and IRBs will scrutinize the near-total single-group origin of the published literature. Phase I sponsors would need to either independently validate key efficacy models pre-IND (i.e., conduct their own tendon-transection studies) or explain to FDA why Sikiric group data is sufficient preclinical support. Independent replication is not a barrier, but it represents additional upfront cost (6–18 months, $500K–$2M).
📌
Endpoint Selection Challenge
BPC-157's multi-system activity is mechanistically interesting but creates a clinical trial problem: which indication to study first? A scattered preclinical portfolio makes endpoint selection and primary indication choice difficult. Focused trials tend to succeed; platform trials across multiple indications are expensive and dilute the signal. The field needs a champion indication with robust animal-to-human translational face validity.
Editorial Position — Path Forward: PeptideReport.ai holds that the most important contribution the research peptide clinical community could make for BPC-157 is a rigorous prospective observational registry — systematic collection of clinician-administered cases with standardized outcome measures (VISA scores, imaging, adverse events). A well-designed registry would: (1) provide Level III evidence; (2) generate safety signal data to support an IND application; (3) help identify the optimal indication and dose for the first Phase I/IIa; and (4) demonstrate to regulatory agencies that the clinical community can produce rigorous methodology around research compounds. This is achievable without a pharmaceutical sponsor, with academic institutional support, and would represent a meaningful step from the current evidence vacuum.
SD
Dr. Scott DelBoccio, DMD
Founder, PeptideReport.ai · Physician-Authored Research Platform
Dr. Scott DelBoccio, DMD is a retired dentist with thirty years of clinical practice — including a hormone-therapy and regenerative wellness practice built around individual bloodwork, national lecturing on advanced dental and surgical techniques, mentoring new dentists on practice management, and innovating dental and laser procedures now used throughout North America — who is now heavily involved in peptide research and development, building beginner-to-advanced optimization frameworks calibrated to the individual, and holds workshops and lectures on peptide therapeutics for other clinicians and researchers. BPC-157 is one of the most widely discussed research peptides in clinical communities — and one of the most important to approach with full epistemic transparency. The complete absence of human clinical trial data is the defining fact about BPC-157 in 2025; this profile presents the preclinical evidence faithfully while making that limitation impossible to miss. The profile covers the molecular structure, six mechanistic pathways, multi-system tissue target map, five preclinical study cards with the replication gap analysis, regulatory and sourcing considerations, the mechanistic basis for the BPC-157 + TB-500 stack, and a forward-looking analysis of what it would take to move BPC-157 from Level V to Level I evidence. Consistent with every profile on this site, no self-administration dosing, reconstitution, or injection instructions are published here — that guidance belongs with a physician and pharmacist, not a web page. PeptideReport.ai is committed to honest, evidence-graded content that serves physicians and high-literacy research candidates. Nothing on this page constitutes prescribing guidance, clinical recommendation, or a patient-provider relationship.
Frequently Asked Questions
BPC-157 · Evidence-Graded Answers · Level V Preclinical Status
Is BPC-157 legal, and how is it typically obtained?
BPC-157 is not an FDA-approved drug, but it is also not a scheduled controlled substance — it exists as a research compound most commonly accessed through licensed 503A/503B compounding pharmacies under physician oversight. Research-chemical websites selling BPC-157 for "laboratory use only" are not held to the sterility, purity, or GMP standards required of a compounding pharmacy, and their purity claims are not independently verifiable. Anyone considering BPC-157 should raise sourcing and legal access with a physician and licensed pharmacist rather than an online retailer.
What does the research actually show for healing and recovery?
The published evidence is exclusively preclinical (Evidence Level V) — rodent and cell-culture studies showing accelerated Achilles tendon tensile-strength recovery, faster gastric ulcer healing, and reduced muscle atrophy in corticosteroid-treated animals, drawn almost entirely from one Croatian research group. These findings are mechanistically consistent and describe real biological activity in animal models, but they have never been tested in a controlled human trial, so any recovery benefit in people remains unproven. This profile's Preclinical Evidence Review and Replication Gap sections lay out that record and its limits in full.
Is BPC-157 FDA-approved?
No. BPC-157 has no FDA-approved indication, no published Phase I human safety trial, and no IND on file for efficacy evaluation, as this profile's Path to Human Evidence section details. It is available only as a compounded research substance, not as an approved pharmaceutical, and peptide-compounding eligibility generally has been an active and evolving area of FDA review.
What are the known risks and safety concerns?
In rodent toxicology, BPC-157 has not shown acute organ toxicity at research doses, but no human long-term safety data exist. The main theoretical concern is mechanistic: its VEGF-upregulating activity — the same pathway that drives new blood vessel growth in tissue repair — is also implicated in tumor angiogenesis, so it is considered inappropriate for anyone with active or recent malignancy. Compounded product quality varies by source, and pregnancy or reproductive safety has never been studied. A physician should review any research candidate's full health history before this compound is considered.
How is BPC-157 actually studied in research settings?
Published research uses fixed animal-model protocols — for example, 10 mcg/kg administered daily by subcutaneous or intraperitoneal injection in the rodent tendon and gastric-ulcer studies summarized on this page — as a controlled experimental variable, not a self-administration schedule. No human dose-finding (Phase I) trial has ever been conducted, so no established human dose, frequency, or duration exists; the Path to Human Evidence section outlines the trial design that would be needed to generate one. Anyone interested in BPC-157 should raise it with a physician rather than translate an animal research protocol into personal use.
Is there a meaningful evidence difference between oral and injectable forms?
Both routes carry Level V evidence only, with no human pharmacokinetic data, but their preclinical rationale differs. Subcutaneous administration bypasses gastrointestinal degradation entirely and is the route used in nearly all published efficacy studies, while oral BPC-157 (typically as the Arginate salt) relies on the peptide's unusual gastric-acid stability for an estimated 15–30% bioavailability in rodents only. Oral dosing may have theoretical appeal for GI-targeted use given direct mucosal contact, but rodent bioavailability figures cannot be assumed to translate to humans, and a physician is best positioned to weigh route selection for any research context.